Trial Profile
An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial Pneumonia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Amikacin (Primary)
- Indications Gram-negative infections; Nosocomial pneumonia; Ventilator associated pneumonia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Bayer
- 17 Feb 2016 According to ClinicalTrials.gov record,primary end points has been revised.
- 24 Dec 2009 New trial record